Amin, AlpeshKeshishian, AXie, LBaşer, OnurPrice, KVo, LSingh, PBruno, AMardekian, JTan, WSinghal, SPatel, COdell, KTrocio J.2019-02-282019-02-282019-02-282019-02-282015Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. (November 7-11, 2015). Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. American Heart Association (AHA) Scientific Sessions 2015. Orlando, FL.https://hdl.handle.net/20.500.11779/850Onur Başer (MEF Author)##nofulltext##...eninfo:eu-repo/semantics/closedAccessConference Object